Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

State/Territory-Coordinated Distribution System for COVID-19 Monoclonal Antibody Therapeutics

Monoclonal antibodies (or mAbs) are a critical tool in fighting the COVID-19 pandemic, and the U.S. Department of Health and Human Services (HHS) is committed to fair and equitable access to these important products. A surge in the Delta variant coupled with low vaccination rates in certain areas of the country contributed to an increase in COVID-19 over the July-August timeframe.

As a result, the HHS Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) implemented a State and Territory-Coordinated Distribution System for mAbs on September 13, 2021, similar to the process used from November 2020 to February 2021.


Step 1
HHS/ASPR
announces
distribution Monday
Step 2
State/territorial
health departments
allocate product to
administration
Step 3
Administration
sites  dispense
mAbs to eligible
patients
Step 4
Administration sites
report product utilization
and stock on hand on
Wednesdays by 11:59 PM ET
View Distribution
Tables >>
About Receiving
Product >>
Patient
Eligibility >>
Reporting
Requirements >>


Questions?

If you have questions about the new state/territory coordinated distribution system,
check out our frequently asked questions section.

View All FAQs >>

  • This page last reviewed: October 01, 2021